checkAd

    ADVR mit der Wunderdroge "R"! Heute wurde das Zulassungsansuchen gestellt! - 500 Beiträge pro Seite

    eröffnet am 31.07.01 19:29:33 von
    neuester Beitrag 09.08.01 15:20:34 von
    Beiträge: 2
    ID: 447.583
    Aufrufe heute: 0
    Gesamt: 379
    Aktive User: 0


     Durchsuchen

    Begriffe und/oder Benutzer

     

    Top-Postings

     Ja Nein
      Avatar
      schrieb am 31.07.01 19:29:33
      Beitrag Nr. 1 ()
      Ich weiß hier gibt es ein paar ADVR Aktionäre an Bord! die wird folgende Meldung besonders freuen!

      Advanced Viral Research Corp. Announces Submission of an

      Investigational New Drug Application to the FDA for Product R

      Business Editors, Health/Medical Writers

      YONKERS, N.Y.--(BUSINESS WIRE)--July 31, 2001--Advanced Viral Research Corp. (OTCBB:ADVR) today announced the submission of an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to begin Phase I clinical trials of Product R as a topical treatment for genital warts caused by human papilloma virus (HPV) infection.

      The Centers for Disease Control and Prevention has estimated that nearly one million new cases of genital warts are diagnosed every year in the United States. Despite the high prevalence of genital warts, existing therapy is often painful, expensive and ineffective. ADVR believes there is a need for more effective and better tolerated therapeutic options. Product R appears to stimulate the pro-inflammatory immune responses required to combat viral infections, such as the human papilloma virus. Upon approval of the IND application by the FDA, Advanced Viral Research Corp. will begin Phase I studies to evaluate safety in humans. Phase I clinical trials cannot begin until the FDA approves the IND application. There is no assurance that the FDA will approve this IND application.

      "The submission of this IND to the FDA marks a most important milestone in the history of Advanced Viral Research Corp.", stated Shalom Z. Hirschman, MD, President and CEO of Advanced Viral Research Corp. "Our scientists have produced the prodigious amount of research required to establish the descriptive platform of the chemistry and pharmacology of Product R. This platform will serve for all future IND applications to the FDA for Product R. We look forward to receiving approval from the FDA for this IND filing and are preparing to move ahead with subsequent IND filings, with the guidance of our FDA consultants, GloboMax LLC. It is our objective to investigate the major therapeutic uses of Product R in clinical trials as soon as possible."

      Product R is a non-toxic peptide nucleic acid-type immunomodulator that appears to stimulate the proinflammatory responses required to combat viral infections such as AIDS and human papilloma virus and to dampen aberrant autoimmune-type inflammatory responses, such as occur in patients with rheumatoid arthritis. Therefore, Product R has been termed a "switch-type" immunomodulator. Product R has shown promise in its ability to mitigate the toxic side-effects of other drugs, including those used to treat HIV infection and chemotherapeutic drugs employed in the treatment of cancers.

      Advanced Viral Research Corp., based in Yonkers, New York, is a biopharmaceutical company dedicated to improving patients` lives by researching, developing and bringing to market new, and effective therapies for viral and other diseases.

      For further information regarding Advanced Viral Research Corp., please visit our website at www.adviral.com

      Note: This news release contains forward-looking statements that involve risks associated with clinical development, regulatory approvals, including application to the FDA, product commercialization and other risks described from time to time in the SEC reports filed by ADVR. Product R is not approved by the U.S. Food and Drug Administration or any comparable agencies of any other countries. ADVR undertakes no obligation to update or revise the information contained in this announcement whether as a result of new information, future events or circumstances or otherwise.

      Zwar ist der Hauptteil der Phantasie, das "R" AIDS heilen soll, nicht mehr vorhanden, dennoch ist "R" ein Produkt mit Zukunftsaussichten!
      Der HPV Virus gilt als einer der Mitverursacher von Gebärmuterkrebs! R soll die "proinflammatory" Reaktionen stimulieren die notwendig sind gegen virale Erkrankungen anzukämpfen! (AIDS, HPV usw) Dämpft auch rheumatische Atritis und verspricht auch die Nebenwirkungen von starken Medikamenten zu dämpfen wie sie in der Krebstherapie und in der AIDS - Therapie vorkommen!

      Für mich immer noch ein sher gutes Medikament, das auf seine Zulassung wartet!

      morchel
      http://www.zockstocks.com
      Avatar
      schrieb am 09.08.01 15:20:34
      Beitrag Nr. 2 ()
      ADVR scheint nun endlich gen Norden zu laufen!!!
      KZ 1 Dollar in einem Monat


      Beitrag zu dieser Diskussion schreiben


      Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
      Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie
      hier
      eine neue Diskussion.
      ADVR mit der Wunderdroge "R"! Heute wurde das Zulassungsansuchen gestellt!